Trial · NCT00842712
Participant flow49
How many started, completed or left each group, period by period.
1 to 20 of 49
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Safety Run-in Part | STARTED | Safety run-in Part: Cil (1000 mg) + Cetuximab + Cis + Gem | 3 | |
| Safety Run-in Part | STARTED | Safety run-in Part: Cil (1000 mg) + Cetuximab + Cis + Vin | 3 | |
| Safety Run-in Part | STARTED | Safety run-in Part: Cil (2000 mg) + Cetuximab + Cis + Gem | 3 | |
| Safety Run-in Part | STARTED | Safety run-in Part: Cil (2000 mg) + Cetuximab + Cis + Vin | 3 | |
| Safety Run-in Part | STARTED | Randomized Part: Cil (Once Weekly) + Cetuximab + Chemotherapy | 0 | |
| Safety Run-in Part | STARTED | Randomized Part: Cil (Twice Weekly) + Cetuximab + Chemotherapy | 0 | |
| Safety Run-in Part | STARTED | Randomized Part: Cetuximab + Chemotherapy | 0 | |
| Safety Run-in Part | COMPLETED | Safety run-in Part: Cil (1000 mg) + Cetuximab + Cis + Gem | 0 | |
| Safety Run-in Part | COMPLETED | Safety run-in Part: Cil (1000 mg) + Cetuximab + Cis + Vin | 1 | |
| Safety Run-in Part | COMPLETED | Safety run-in Part: Cil (2000 mg) + Cetuximab + Cis + Gem | 3 | |
| Safety Run-in Part | COMPLETED | Safety run-in Part: Cil (2000 mg) + Cetuximab + Cis + Vin | 2 | |
| Safety Run-in Part | COMPLETED | Randomized Part: Cil (Once Weekly) + Cetuximab + Chemotherapy | 0 | |
| Safety Run-in Part | COMPLETED | Randomized Part: Cil (Twice Weekly) + Cetuximab + Chemotherapy | 0 | |
| Safety Run-in Part | COMPLETED | Randomized Part: Cetuximab + Chemotherapy | 0 | |
| Safety Run-in Part | NOT COMPLETED | Safety run-in Part: Cil (1000 mg) + Cetuximab + Cis + Gem | 3 | |
| Safety Run-in Part | NOT COMPLETED | Safety run-in Part: Cil (1000 mg) + Cetuximab + Cis + Vin | 2 | |
| Safety Run-in Part | NOT COMPLETED | Safety run-in Part: Cil (2000 mg) + Cetuximab + Cis + Gem | 0 | |
| Safety Run-in Part | NOT COMPLETED | Safety run-in Part: Cil (2000 mg) + Cetuximab + Cis + Vin | 1 | |
| Safety Run-in Part | NOT COMPLETED | Randomized Part: Cil (Once Weekly) + Cetuximab + Chemotherapy | 0 | |
| Safety Run-in Part | NOT COMPLETED | Randomized Part: Cil (Twice Weekly) + Cetuximab + Chemotherapy | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00842712/flow